OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Neurology is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Transmembrane protein interacts with α-synuclein to confer risk of PD	596
Lymphatic propagation of α-synuclein	375
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	365
Brain stimulation aids walking after spinal injury	338
Ventricular enlargement caused by aducanumab	282
ANA2025 marks important milestones for the ANA and NINDS	269
Reply to ‘Perils and pitfalls of near-death experience research’	260
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	258
Neural cell state shifts and fate loss in ageing and age-related diseases	252
Global synergistic actions to improve brain health for human development	244
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	238
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	235
Disease-specific modifications of tau protein	229
Continuous levodopa production by an artificial enzyme	224
TREM2 mediates phagocytosis in glioblastoma	222
Study reveals new ALS risk genes	177
SEQUINS — a new initiative to address disparities in neurology	175
Nir Giladi (1955–2024)	165
Spinal muscular atrophy treatment in utero	163
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	151
Mitochondrial DNA instability in Huntington disease	147
The role of the gut microbiota in multiple sclerosis	144
The impact of rare genetic variants on Alzheimer disease	143
The Digitized Memory Clinic	122
Imperatives and co-benefits of research into climate change and neurological disease	120

Psychosis-causing lesions mapped to a hippocampal circuit	119
Neuroinflammation predicts cognitive decline in FTD	113
Ultrasound lets gene therapy into the brain	111
Menopause influences tau pathology	111
Implications of AD plasma and PET biomarker discordance	111
Amyloid plaques: hotspots for microglial turnover	110
Brain volume is associated with cognition in MS	110
Challenges of combining multimodal data in assessment of people with traumatic brain injury	106
MRI-based deep learning for TLE diagnosis	105
Gene therapy for seizures in focal cortical dysplasia	102
Neurological care for LGBT+ people	94
Parkinson disease pathology can originate in the kidney	94
Author Correction: Viral pathogens increase risk of neurodegenerative disease	92
Precision neuroimmunology in multiple sclerosis — the horizon is near	91
First trials test targeting of α-synuclein for Parkinson disease	91
Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis	90
The challenges of anti-tau therapeutics in Alzheimer disease	85
Management of freezing of gait — mechanism-based practical recommendations	84
α-Synuclein pathology as a target in neurodegenerative diseases	80
Diversity, equity and inclusion in neurology	80
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	79
Food is brain medicine — relevance and translation to neurology	76
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	76
Neurosteroids alleviate seizures in rats	74
Glymphatic dysfunction in PD clinical progression	72
A new biological classification for Parkinson disease	69
Addressing disparities in neurology by building the workforce in LMICs	67
Ultrasound ablation treatment for PD	65
Thalamic inflammation — a therapeutic target for brain injury?	63
New IDEAS about amyloid, race and dementia disparities	62
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	62
Coeliac disease as a model for understanding multiple sclerosis	62
From the prodromal stage of multiple sclerosis to disease prevention	61
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	61
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	61
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	61